News Release
View printer-friendly version
|
<< Back |
ZUG, Switzerland and CAMBRIDGE, Mass.,
2018
Date: Thursday, February 22, 2018
Presentation: 8:
Webcast available under Investor Relations tab at CRISPRTx.com
Date: Tuesday, March 13, 2018
Presentation: 3:20-3:45 PM ET
Date: March 27th, 2018
17th Annual
Date: March 28th, 2018
Presentation:
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge,
MEDIA CONTACT:
WCG on behalf of CRISPR
+1 347-658-8290 jpaganelli@wcgworld.com
INVESTOR CONTACT:
+1 617.307.7227 chris.erdman@crisprtx.com
+1 339-970-2843 chris.brinzey@westwicke.com